Reported 12 months ago
Antro, a subsidiary of GUANG Light Biotechnology focusing on new drug development and marketing, announced a major breakthrough as their Enterovirus 71 vaccine (EnVAX-A71) successfully completed Phase III clinical trial unblinding with a high protection rate of 99.21%. Investors are thrilled with anticipation, believing that the biotechnology sector is poised for significant growth. Antro plans to expand vaccine distribution starting from 2024 and has already signed a sales contract with VABIOTECH, Vietnam's largest state-owned vaccine company, aiming to enter the Southeast Asian and Chinese newborn markets.
Source: YAHOO